Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial

por Shi, Aixin, Xie, Panpan, Nielsen, Lasse Lykke, Skjøth, Trine Vang, He, Xuemei, Haugaard, Sine Pfeiffer
Publicado 2020

Hypoglycemia in Type 1 Diabetic Pregnancy: Role of preconception insulin aspart treatment in a randomized study

por Heller, Simon, Damm, Peter, Mersebach, Henriette, Skjøth, Trine Vang, Kaaja, Risto, Hod, Moshe, Durán-García, Santiago, McCance, David, Mathiesen, Elisabeth R.
Publicado 2010

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

por Niskanen, Leo, Leiter, Lawrence A, Franek, Edward, Weng, Jianping, Damci, Taner, Muñoz-Torres, Manuel, Donnet, Jean-Paul, Endahl, Lars, Skjøth, Trine Vang, Vaag, Allan
Publicado 2012

Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30‐week, double‐blind, phas...

por Ji, Linong, Dong, Xiaolin, Li, Yiming, Li, Yufeng, Lim, Soo, Liu, Ming, Ning, Zu, Rasmussen, Søren, Skjøth, Trine Vang, Yuan, Guoyue, Eliaschewitz, Freddy G.
Publicado 2021

Early Weight Loss with Liraglutide 3.0 mg Predicts 1‐Year Weight Loss and is Associated with Improvements in Clinical Markers

por Fujioka, Ken, O'Neil, Patrick M., Davies, Melanie, Greenway, Frank, C.W. Lau, David, Claudius, Birgitte, Skjøth, Trine Vang, Bjørn Jensen, Christine, P.H. Wilding, John
Publicado 2016